Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Endothelin-1 receptor blockade does not alter the sympathetic and hemodynamic response to acute intermittent hypoxia in men
Limberg, Jacqueline K. , Baker, Sarah E. , Ott, Elizabeth P., Jacob, Dain W. , Scruggs, Zachariah M., Harper, Jennifer L. , Manrique‐Acevedo, Camila , Manrique-Acevedo, Camila M , Baker, Sarah E

Mayo Clinic

Journal of Applied Physiology | August 11, 2022 | Volume: 133 | Issue: 4 | Pages: 867-875

10.1152/japplphysiol.00837.2021 | PMID 35952348 Get It

Repeat exposures to low oxygen (intermittent hypoxia, IH) elicit increases in muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in men. Endothelin (ET) receptor antagonists can attenuate the sympathetic and BP response to IH in rodents; whether these data translate to humans were unclear. We show acute IH results in an increase in ET-1, MSNA, and BP in healthy young men; however, the effect of IH on MSNA and BP does not occur through activation of ET-receptors in healthy young men.
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Attia, Steven , Ganjoo, Kristen N. , Agulnik, Mark , Rushing, Daniel A., Livingston, Michael B. , Wright, Jennifer , Chawla, Sant P. , Okuno, Scott H. , Riedel, Richard F. , Ryan, Christopher W. , Maki, Robert G. , Reinke, Denise , Davis, Lara E , Maki, Robert G , Riedel, Richard F , Bolejack, Vanessa , George, Suzanne , Loggers, Elizabeth T , Reinke, Denise K. , Davis, Lara E.

Mayo Clinic

Cancer Medicine | August 11, 2022 | Volume: 12 | Issue: 2 | Pages: 1532-1539

10.1002/cam4.5044 | PMID 35950293 Get It

Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of regorafenib in advanced Ewing family sarcomas. Methods Patients with metastatic Ewing family sarcomas (age ≥ 18, ECOG 0–2, good organ function) who had received at least one line of therapy and experienced progression within 6 months of registration were eligible. Prior kinase inhibitors were not allowed. The initial dose of regorafenib was 160 mg oral days 1–21 of a 28‐day cycle. The primary endpoint was estimating progression‐free rate (PFR) at 8 weeks employing RECIST 1.1. Results Thirty patients (median age, 32 years; 33% women [10 patients]; bone primary, 40%; extraskeletal primary, 60%) enrolled at 14 sites. The most common grade 3 or higher toxicities were hypophosphatemia (5 grade 3, 1 grade 4), hypertension (2 grade 3), elevated ALT (2 grade 3). Sixteen patients required dose reductions, most often for hypophosphatemia ( n = 7 reductions in 6 patients); two stopped regorafenib for toxicity. There was one death unrelated to treatment in the 30‐day post‐study period. Median progression‐free survival (PFS) was 14.8 weeks (95% CI 7.3–15.9); PFR at 8 weeks by Kaplan–Meier analysis was 63% (95% CI 46–81%). The RECIST 1.1 response rate was 10%. Median OS was 53 weeks (95% CI 37–106 weeks). Conclusions Regorafenib has modest activity in the Ewing family sarcomas. Toxicity was similar to that seen in approval studies.
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, Robert I. , Bischoff, Lindsay , Ball, Douglas W., Bernet, Victor , Blomain, Erik , Busaidy, Naifa L. , Campbell, Michael J. , Dickson, Paxton V. , Ehya, Hormoz, Guo, Theresa , Holt, Shelby , Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Mandel, Susan J., McIver, Bryan, Raeburn, Christopher D., Rezaee, Rod , Roth, Mara Y. , Scheri, Randall P., Sipos, Jennifer A. , Wang, Thomas N., Wirth, Lori J. , Cassara, Carly J., Darlow, Susan, Haddad, Robert , Duh, Quan‐Yang , Goldner, Whitney Sears , Haymart, Megan R. , Iagaru, Andrei H. , Markovina, Stephanie T. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 925-951

10.6004/jnccn.2022.0040 | PMID 35948029 Get It

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
Gender Diversity in Primary Care Sports Medicine Leadership
Mattson, Laura M., Rosario‐Concepción, Raúl A. , Hurdle, Mark Friedrich B., Pagan‐Rosado, Robert , Clapp, Adrianna D.M. , Maynard, Jennifer R. , Pagán-Rosado, Robert D, Clapp, Adrianna D, Rosario-Concepcion, Raul A , Clapp, Adrianna

Mayo Clinic

Current Sports Medicine Reports | August 10, 2022 | Volume: 21 | Issue: 8 | Pages: 303-308

10.1249/jsr.0000000000000979 | PMID 35946849 Get It

Abstract Diversity, equity, and inclusion have been recognized as important drivers of excellence and innovation in the physician workforce. Given the historical underrepresentation of women in medicine, gender diversity is of interest. In this cross-sectional study, we sought to quantify leadership representation of female physicians in primary care sports medicine settings, including primary care sports medicine fellowship programs, select sports medicine societies, and select sports medicine-related scientific journals. Data were collected by querying the corresponding web site for each fellowship program, society, and journal and analyzed in a descriptive manner. Results showed that fewer female physicians hold primary care sports medicine leadership roles than men do. This work establishes a baseline for female representation in primary care sports medicine leadership; efforts should continue to increase the presence of women in leadership positions.
Adherence to continuous positive airway pressure reduces the risk of 30-day hospital readmission among older adults with comorbid obstructive sleep apnea and cardiovascular disease
Albrecht, Jennifer S. , Bailey, M. Doyinsola , Wickwire, Emerson M. , Somers, Virend K.

Mayo Clinic

Journal of Clinical Sleep Medicine | August 8, 2022 | Volume: 18 | Issue: 12 | Pages: 2739-2744

10.5664/jcsm.10196 | PMID 35934923 Get It

Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review
Ayala, Ivan N. , Aziz, Syed N, Argudo, Jennifer M, Yépez, Mario , Camacho, Mikaela , Ojeda, Diego , Aguirre, Alex S. , Oña, Sebastian, Andrade, Andres F , Vasudhar, Ananya, Moncayo, Juan A , Hassen, Gashaw , Ortíz, Juan Fernando , Tambo, Willians , Ayala, Iván Nicolas

Mayo Clinic

Brain Sciences | August 7, 2022 | Volume: 12 | Issue: 8 | Pages: 1040

10.3390/brainsci12081040 | PMID 36009103 Get It

Ataxia is a constellation of symptoms that involves a lack of coordination, imbalance, and difficulty walking. Hereditary ataxia occurs when a person is born with defective genes, and this degenerative disorder may progress for several years. There is no effective cure for ataxia, so we need to search for new treatments. Recently, interest in riluzole in the treatment of ataxia has emerged. We conducted this systematic review to analyze the safety and efficacy of riluzole for treating hereditary ataxia in recent clinical trials. We conducted a systematic review using PubMed and Google Scholar as databases in search of this relationship. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocols to conduct this study. For inclusion criteria, we included full-text clinical trials on humans written in English and found three clinical trials. We excluded case reports, literature reviews, systematic reviews, and meta-analyses for this analysis. We aimed to evaluate the Scale for the Assessment and Rating of Ataxia (SARA) score, the International Cooperative Ataxia Rating Scale (ICARS) score, and the safety of the medication. Two out of the three clinical trials showed statistically significant clinical improvement in the ICARS and SARA scores, while the other trial did not show improvement in the clinical or radiological outcomes. The drug was safe in all clinical trials. Overall, the results of this analysis of riluzole for the treatment of hereditary ataxia are encouraging. Further clinical trials are needed to investigate the efficacy of riluzole on hereditary ataxia.
The Impact of COVID-19 on Physician–Scientist Trainees and Faculty in the United States: A National Survey
Kwan, Jennifer M. , Noch, Evan , Qiu, Yuqing , Toubat, Omar , Christophers, Briana , Azzopardi, Stephanie A. , Gilmer, Gabrielle , Wiedmeier, Julia E. , Daye, Dania , Wiedmeier, Julia Erin, Wiedmeier-Nutor, Julia E

Mayo Clinic

Academic Medicine | August 5, 2022 | Volume: 97 | Issue: 10 | Pages: 1536-1545

10.1097/acm.0000000000004802 | PMID 35921163 Get It

Abstract Purpose Physician–scientists have long been considered an endangered species, and their extended training pathway is vulnerable to disruptions. This study investigated the effects of COVID-19-related challenges on the personal lives, career activities, stress levels, and research productivity of physician–scientist trainees and faculty. Method The authors surveyed medical students (MS), graduate students (GS), residents/fellows (R/F), and faculty (F) using a tool distributed to 120 U.S. institutions with MD–PhD programs in April–June 2020. Chi-square and Fisher’s exact tests were used to compare differences between groups. Machine learning was employed to select variables for multivariate logistic regression analyses aimed at identifying factors associated with stress and impaired productivity. Results The analyses included 1,929 respondents (MS: n = 679, 35%; GS: n = 676, 35%; R/F: n = 274, 14%; F: n = 300, 16%). All cohorts reported high levels of social isolation, stress from effects of the pandemic, and negative impacts on productivity. R/F and F respondents were more likely than MS and GS respondents to report financial difficulties due to COVID-19. R/F and F respondents with a dual degree expressed more impaired productivity compared with those without a dual degree. Multivariate regression analyses identified impacted research/scholarly activities, financial difficulties, and social isolation as predictors of stress and impaired productivity for both MS and GS cohorts. For both R/F and F cohorts, impacted personal life and research productivity were associated with stress, while dual-degree status, impacted research/scholarly activities, and impacted personal life were predictors of impaired productivity. More female than male respondents reported increased demands at home. Conclusions This national survey of physician–scientist trainees and faculty found a high incidence of stress and impaired productivity related to the COVID-19 pandemic. Understanding the challenges faced and their consequences may improve efforts to support the physician–scientist workforce in the postpandemic period.
BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021 – April 2022
Zambrano, Laura D. , Newhams, Margaret M. , Olson, Samantha M. , Halasa, Natasha , Price, Ashley M. , Orzel, Amber, Boom, Julie A. , Bline, Katherine , Kamidani, Satoshi , Tarquinio, Keiko M. , Schuster, Jennifer E. , Cullimore, Melissa L. , Heidemann, Sabrina M. , Nofziger, Ryan A. , Cameron, Melissa A. , Walker, Tracie C. , Michelson, Kelly N, Coates, Bria M. , Flori, Heidi R. , Mack, Elizabeth H. , Smallcomb, Laura , Gertz, Shira J. , Bhumbra, Samina S. , Bradford, Tamara T. , Levy, Emily R. , Kong, Michele , Irby, Katherine, Zinter, Matt S. , Bowens, Cindy, Crandall, Hillary , Hume, Janet R. , Patel, Manish M, Campbell, Angela P. , Randolph, Adrienne G. , Investigators, for the Overcoming COVID-19, Murdock, Meghan, Gaspers, Mary Glas , Kelley, Connor P. , Irby, Katherine, Sanders, Ronald C., Yates, Masson, Smith, Chelsea , Crane, Katheryn, Lionetti, Geraldina, Murcia-Montoya, Juliana, Villarreal-Chico, Denise, Skura, Adam L., Hakimi, Daniel , Peralta, Harvey, Sea, Yea Ji, Mrotek, Kennis-Grace, Lockwood, Justin M. , Port, Emily, Carson, Imogene A., Chatani, Brandon , Kamidani, Satoshi, Hussaini, Laila, Baida, Nadine, Michelson, Kelly N, Rhodes, Simone T., Khan, Hassan A, Rowan, Courtney M. , Stumpf, Mary, Johnston, Marla , Newhams, Margaret M, Kücükak, Suden, Orzel, Amber O, Chen, Sabrina R., Boutselis, Benjamin J., McCadden, Timothy P. , Stewart, Kasey R, Weller, Edie, Berbert, Laura , He, Jie , Bruno, Ellen R., Goertzen, Lexie A., Drapeau, Noelle M., Martin, Lora , Malloch, Lacy , Harrison, Virginia A., Sanders, Cameron , Patterson, Kayla , Chikere, Chidinma A, Kietzman, Abigail , Sullivan, Melissa, Rinehart, Valerie H., Hoody, Lauren A., Bennett, Paris C., Twinem, Nicole A., Tomcany, Merry, Staat, Mary Allen , Rohlfs, Chelsea C., Wolfe, Amber, Chiotos, Kathleen, Douglas, Rebecca L. , Phengchomphet, Kathlyn, Bickford, Megan M., Wakefield, Lauren E., Hayek, Haya , Romero, Yesenia, Boom, Julie A, Oates, Jennifer N., Maamari, Mia , Bowens, Cindy, Olson, Mady, Zambrano, Laura D, Patel, Manish M, Kamidani, Satoshi , Levy, Emily R , Randolph, Adrienne G , Kong, Michele , Hume, Janet R , Zambrano, Laura D , Staat, Mary A , Gertz, Shira J , Bline, Katherine E , Young, Cameron C. , Sahni, Leila C , Maddux, Aline B. , Chiotos, Kathleen , Hobbs, Charlotte V. , Pannaraj, Pia S. , Schwartz, Stephanie P. , Michelson, Kelly N, Irby, Katherine, Cvijanovich, Natalie Z , Bowens, Cindy, Patel, Manish M, Investigators, for the Overcoming COVID-19, Typpo, Katri , Irby, Katherine, Kamidani, Satoshi, Michelson, Kelly N, Newhams, Margaret M, Orzel, Amber O, Moran, Patrick, Behl, Supriya , Chiotos, Kathleen, Boom, Julie A, Bowens, Cindy, Olson, M, Zambrano, Laura D, Patel, Manish M

Mayo Clinic

Clinical Infectious Diseases | August 4, 2022 | Volume: 76 | Issue: 3 | Pages: e90-e100

10.1093/cid/ciac637 | PMID 35924406 Get It

Abstract Background Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. Methods In a multicenter, case-control, public health investigation of children ages 5–18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. Results We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]: .16; 95% CI: .10–.26), including among children ages 5–11 years (aOR: .22; 95% CI: .10–.52), ages 12–18 years (aOR: .10; 95% CI: .05–.19), and during the Delta (aOR: .06; 95% CI: .02–.15) and Omicron (aOR: .22; 95% CI: .11–.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR: .08; 95% CI: .03–.22) in 12–18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Conclusions Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5–18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated.
Beyond service education: Impacting the human experience with sustained training utilizing the Experience Model of Communication
Packard, Jennifer S., Brustad, Rebecca A., Hoplin, Jane M., Stevens, Sheila K., Packard, Jennifer S., Brustad, Rebecca

Mayo Clinic

Patient Experience Journal | August 4, 2022 | Volume: 9 | Issue: 2 | Pages: 87-93

10.35680/2372-0247.1691 Get It

Patients scheduling or checking in for medical appointments often share with frontline employees’ details of their stories, including their worries, prior negative experiences, and hopes. These interactions require employees to not only complete their task, but also to be mindfully present, picking up on important social cues and showing appropriate emotional congruence and empathic understanding. Based on a review of recorded patient calls, a gap was identified in the communication skills of desk and scheduling staff at this large academic medical center, and a sustained training program was created to fill this gap. The training is centered on an evolving set of theoretical principles and skills that have come to be known as the Experience Model of Communication (XMOC). We wanted to understand if training in XMOC, a set of skills essential for healthcare providers, would also be beneficial for frontline staff. The training was evaluated with pre/post surveys, listening sessions, an annual evaluation, and quarterly tracking of patient experience scores, and findings suggest that the training content has had a positive impact. We continue to build and evaluate the training program to identify and refine the elements that make up XMOC and the most effective ways to transfer that learning to the staff who benefit. Experience Framework This article is associated with the Staff & Provider Engagement lens of The Beryl Institute Experience Framework (https://www.theberylinstitute.org/ExperienceFramework). Access other PXJ articles related to this lens. Access other resources related to this lens.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
Rosen, Allyson , AGREEDementia, members of, Arias, Jalayne J. , Ashford, J. Wesson , Blacker, Deborah , Chhatwal, Jasmeer P. , Chin, Nathan , Clark, Lindsay R. , Denny, Sharon, Gleason, Carey E. , Heidebrink, Judith L. , Henderson, Victor W. , Lavacot, James A., Lingler, Jennifer H. , Menon, Malavika, Nosheny, Rachel L. , Oliveira, Fabricio Ferreira de , Parker, Monica W. , Rahman‐Filipiak, Annalise , Revoori, Anwita, Rumbaugh, Malia, Sanchez, Danurys , Schindler, Suzanne E. , Toy, Leslie, Tyrone, Jamie, Walter, Sarah , Wang, Li-san, Zallen, Doris T. , Aggarwal, Neelum T. , AGREEDementia, members of, Chin, Nathan A., Goldman, Jill , Grill, Joshua D. , Menon, Malavika, Schwarz, Christopher G. , Wijsman, Ellen M.

Mayo Clinic

Journal of Alzheimer's Disease | August 2, 2022 | Volume: 90 | Issue: 3 | Pages: 953-962

10.3233/jad-220458 | PMID 35938255 Get It

The brain changes of Alzheimer’s disease and other degenerative dementias begin long before cognitive dysfunction develops, and in people with subtle cognitive complaints, clinicians often struggle to predict who will develop dementia. The public increasingly sees benefits to accessing dementia risk evidence (DRE) such as biomarkers, predictive algorithms, and genetic information, particularly as this information moves from research to demonstrated usefulness in guiding diagnosis and clinical management. For example, the knowledge that one has high levels of amyloid in the brain may lead one to seek amyloid reducing medications, plan for disability, or engage in health promoting behaviors to fight cognitive decline. Researchers often hesitate to share DRE data, either because they are insufficiently validated or reliable for use in individuals, or there are concerns about assuring responsible use and ensuring adequate understanding of potential problems when one’s biomarker status is known. Concerns include warning people receiving DRE about situations in which they might be compelled to disclose their risk status potentially leading to discrimination or stigma. The Advisory Group on Risk Evidence Education for Dementia (AGREEDementia) welcomes all concerned with how best to share and use DRE. Supporting understanding in clinicians, stakeholders, and people with or at risk for dementia and clearly delineating risks, benefits, and gaps in knowledge is vital. This brief overview describes elements that made this group effective as a model for other health conditions where there is interest in unfettered collaboration to discuss diagnostic uncertainty and the appropriate use and communication of health-related risk information.